JPWO2020091036A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020091036A5
JPWO2020091036A5 JP2020554977A JP2020554977A JPWO2020091036A5 JP WO2020091036 A5 JPWO2020091036 A5 JP WO2020091036A5 JP 2020554977 A JP2020554977 A JP 2020554977A JP 2020554977 A JP2020554977 A JP 2020554977A JP WO2020091036 A5 JPWO2020091036 A5 JP WO2020091036A5
Authority
JP
Japan
Prior art keywords
edaravone
suspension
dispersant
humans
suspension according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020554977A
Other languages
English (en)
Japanese (ja)
Other versions
JP7274502B2 (ja
JPWO2020091036A1 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2019/043013 external-priority patent/WO2020091036A1/ja
Publication of JPWO2020091036A1 publication Critical patent/JPWO2020091036A1/ja
Publication of JPWO2020091036A5 publication Critical patent/JPWO2020091036A5/ja
Priority to JP2023075654A priority Critical patent/JP7828317B2/ja
Application granted granted Critical
Publication of JP7274502B2 publication Critical patent/JP7274502B2/ja
Priority to JP2025168147A priority patent/JP2026010001A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020554977A 2018-11-02 2019-11-01 経口投与用エダラボン懸濁剤 Active JP7274502B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023075654A JP7828317B2 (ja) 2018-11-02 2023-05-01 経口投与用エダラボン懸濁剤
JP2025168147A JP2026010001A (ja) 2018-11-02 2025-10-06 経口投与用エダラボン懸濁剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018207646 2018-11-02
JP2018207646 2018-11-02
PCT/JP2019/043013 WO2020091036A1 (ja) 2018-11-02 2019-11-01 経口投与用エダラボン懸濁剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023075654A Division JP7828317B2 (ja) 2018-11-02 2023-05-01 経口投与用エダラボン懸濁剤

Publications (3)

Publication Number Publication Date
JPWO2020091036A1 JPWO2020091036A1 (ja) 2021-09-24
JPWO2020091036A5 true JPWO2020091036A5 (cg-RX-API-DMAC7.html) 2022-11-09
JP7274502B2 JP7274502B2 (ja) 2023-05-16

Family

ID=70463399

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020554977A Active JP7274502B2 (ja) 2018-11-02 2019-11-01 経口投与用エダラボン懸濁剤
JP2023075654A Active JP7828317B2 (ja) 2018-11-02 2023-05-01 経口投与用エダラボン懸濁剤
JP2025168147A Pending JP2026010001A (ja) 2018-11-02 2025-10-06 経口投与用エダラボン懸濁剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023075654A Active JP7828317B2 (ja) 2018-11-02 2023-05-01 経口投与用エダラボン懸濁剤
JP2025168147A Pending JP2026010001A (ja) 2018-11-02 2025-10-06 経口投与用エダラボン懸濁剤

Country Status (20)

Country Link
US (6) US10987341B2 (cg-RX-API-DMAC7.html)
EP (2) EP3875085B1 (cg-RX-API-DMAC7.html)
JP (3) JP7274502B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210087490A (cg-RX-API-DMAC7.html)
CN (4) CN117379369A (cg-RX-API-DMAC7.html)
AR (1) AR116967A1 (cg-RX-API-DMAC7.html)
AU (2) AU2019369843A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021008197A2 (cg-RX-API-DMAC7.html)
DK (1) DK3875085T3 (cg-RX-API-DMAC7.html)
ES (1) ES2991523T3 (cg-RX-API-DMAC7.html)
FI (1) FI3875085T3 (cg-RX-API-DMAC7.html)
HU (1) HUE068117T2 (cg-RX-API-DMAC7.html)
IL (2) IL319280A (cg-RX-API-DMAC7.html)
MX (3) MX2021005144A (cg-RX-API-DMAC7.html)
PH (1) PH12021550988A1 (cg-RX-API-DMAC7.html)
PL (1) PL3875085T3 (cg-RX-API-DMAC7.html)
PT (1) PT3875085T (cg-RX-API-DMAC7.html)
SG (1) SG11202104365QA (cg-RX-API-DMAC7.html)
TW (1) TWI924629B (cg-RX-API-DMAC7.html)
WO (1) WO2020091036A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019167178A1 (ja) * 2018-02-28 2019-09-06 田辺三菱製薬株式会社 3-メチル-1-フェニル-2-ピラゾリン-5-オン原薬の分析方法、筋萎縮性側索硬化症の治療および筋萎縮性側索硬化症の進行抑制、ならびに、3-メチル-1-フェニル-2-ピラゾリン-5-オン原薬を含む薬剤の製造方法
BR112021008197A2 (pt) 2018-11-02 2021-08-03 Mitsubishi Tanabe Pharma Corporation suspensão de edaravone para administração oral
US11826352B2 (en) 2018-11-02 2023-11-28 Mitsubishi Tanabe Pharma Corporation Edaravone suspension for oral administration
IN201921028874A (cg-RX-API-DMAC7.html) * 2019-07-18 2021-01-22
JPWO2022102737A1 (cg-RX-API-DMAC7.html) 2020-11-12 2022-05-19
US12194025B2 (en) 2020-11-12 2025-01-14 Mitsubishi Tanabe Pharma Corporation Pharmaceutical composition for oral administration of edaravone and method of administering same
GB202103807D0 (en) 2021-03-18 2021-05-05 Johnson Matthey Plc A crystalline salt of edaravone, processes for the preparation and use thereof
EP4473965A4 (en) 2022-02-03 2026-01-07 Mitsubishi Tanabe Pharma Corp MEDICAL AGENT FOR THE TREATMENT OR SUPPRESSION OF THE PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS
WO2024005187A1 (ja) 2022-07-01 2024-01-04 田辺三菱製薬株式会社 組成物、およびエダラボンの応答可能性の評価方法
WO2024172852A1 (en) 2023-02-16 2024-08-22 Slayback Pharma Llc Stable pharmaceutical compositions of edaravone
CN118178328A (zh) * 2024-03-21 2024-06-14 药云(西安)医药技术有限公司 依达拉奉包埋物制备方法与其口服制剂
US20260130849A1 (en) * 2024-11-13 2026-05-14 Tulex Pharmaceuticals, Inc. Edaravone Oral Solution Compositions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61263917A (ja) 1985-05-20 1986-11-21 Mitsubishi Yuka Yakuhin Kk 脳機能正常化剤
JPH07121861B2 (ja) 1986-11-25 1995-12-25 三菱化学株式会社 3−メチル−1−フエニル−2−ピラゾロン−5−オンを含有する安定な注射剤
JPH0531523A (ja) 1991-07-26 1993-02-09 Aichi Steel Works Ltd ロ−ラ回転数・間隙測定可能な圧延機用ロ−ラガイド装置
JP3402195B2 (ja) * 1997-05-14 2003-04-28 千寿製薬株式会社 再分散性の良い水性懸濁液剤
JPH1120463A (ja) 1997-06-30 1999-01-26 Zexel Corp 車両用デュアルエアコン
ES2248144T3 (es) 2000-10-24 2006-03-16 Mitsubishi Pharma Corporation Medicamentos para tratar la esclerosis lateral amiotrofica (ela).
JP2004091441A (ja) * 2002-09-04 2004-03-25 Mitsubishi Pharma Corp ピラゾロン誘導体を含有する経口投与製剤
EP1714960B1 (en) 2004-02-09 2018-03-28 Mitsubishi Tanabe Pharma Corporation Novel therapeutic agent for amyotrophic lateral sclerosis (als) or disease attributable to als
JP5836004B2 (ja) 2010-08-12 2015-12-24 日新化成株式会社 可溶化剤
CN102824356A (zh) 2012-09-25 2012-12-19 江西中医学院 一种黄芩苷纳晶混悬剂、纳晶干粉及其制备方法
US9642843B2 (en) 2013-02-27 2017-05-09 The Regents Of The University Of Michigan Pharmaceutical compounds and use of same in cancer and tauopathies
JP6336246B2 (ja) * 2013-03-13 2018-06-06 大同化成工業株式会社 ナノ粒子化製剤及びその製造方法
CN105878171A (zh) * 2014-12-22 2016-08-24 南京海恒医药科技有限公司 一种依达拉奉新制剂及其制备方法
CN107205935A (zh) 2015-01-20 2017-09-26 默克专利股份有限公司 用聚乙烯醇作载体聚合物的化合物固体分散体
EP3427724A4 (en) 2016-03-10 2019-11-13 Sumitomo Dainippon Pharma Co., Ltd. COMPOSITION WITH FINE PARTICLES AND METHOD FOR THE MANUFACTURE THEREOF
CN109125261B (zh) * 2016-03-16 2021-11-30 苏州澳宗生物科技有限公司 依达拉奉剂型
EP3785703A1 (en) 2017-01-17 2021-03-03 Treeway TW001 B.V. Treatment comprising oral or gastric administration of edaravone
BR112019014712A2 (pt) * 2017-01-17 2020-02-18 Treeway Tw001 B.V. Tratamento médio que compreende a administração entérica de edaravona
KR20200024868A (ko) * 2017-07-06 2020-03-09 트리웨이 티더블유001 비.브이. 산화성 스트레스-매개 신경퇴행성 질환의 경구 치료에 사용하기 위한 에다라본의 용도
BR112021008197A2 (pt) * 2018-11-02 2021-08-03 Mitsubishi Tanabe Pharma Corporation suspensão de edaravone para administração oral
IN201921028874A (cg-RX-API-DMAC7.html) * 2019-07-18 2021-01-22

Similar Documents

Publication Publication Date Title
JP2026010001A5 (cg-RX-API-DMAC7.html)
JP5607083B2 (ja) リルゾール水性懸濁液
JP6449205B2 (ja) ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
JP2016503762A5 (cg-RX-API-DMAC7.html)
RU2011145278A (ru) Композиции клозапина с контролируемым высвобождением
JP2004503484A (ja) 多孔質セレコキシブマトリックスおよびその製造方法
TW201023912A (en) Pharmaceutical suspension
JP2021169504A (ja) アプレピタント経口液体製剤
JP2021169510A5 (cg-RX-API-DMAC7.html)
JP2016513625A5 (cg-RX-API-DMAC7.html)
EA027720B1 (ru) Способ получения пленки, содержащей свободное основание силденафила
HK1046366A1 (en) Ziprasidone suspension
ES2553107T3 (es) Composición anti-inflamatoria basada en compuestos de estroncio
EP0594770B1 (fr) Compositions ophtalmiques a base d'oxicam ou de derives d'oxicam
CN1642537A (zh) 用于硬壳胶囊的布洛芬溶液
WO2006132342A1 (ja) ロフルミラスト点眼液
JPWO2008099615A1 (ja) 微粒子油性懸濁液を含む医薬組成物
KR20090098610A (ko) 입자크기가 조절된 술포데히드로아비에트산을 함유한쓴맛이 저감된 경구용 액상 조성물
WO1997041864A1 (en) Ophthalmic preparations
JP5922609B2 (ja) 2−アミノ−3−(4−ブロモベンゾイル)フェニル酢酸含有水性組成物
CN102482316A (zh) 熊去氧胆酸-合成水滑石-丙烯酸树脂杂合体、包含该杂合体的药物组合物及其制备方法
KR102778468B1 (ko) 저점도 점안 조성물의 제조방법
RU2021115473A (ru) Суспензия эдаравона для перорального введения
KR970001712B1 (ko) 개선된 저점도의 고농도 황산바륨 조영제 및 그의 제조방법
JPH05186348A (ja) 水性懸濁液剤の製造法